日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

FDA批准摘要:恩福妥单抗联合帕博利珠单抗治疗局部晚期或转移性尿路上皮癌

Brave, Michael H; Maguire, William F; Weinstock, Chana; Zhang, Hui; Gao, Xin; Li, Fang; Yu, Jingyu; Fu, Wentao; Zhao, Hong; Pierce, William F; Chang, Elaine; Dinin, Jeannette; Fiero, Mallorie H; Rahman, Nam Atiqur; Tang, Shenghui; Pazdur, Richard; Kluetz, Paul G; Amiri-Kordestani, Laleh; Suzman, Daniel L

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

FDA批准摘要:Belzutifan用于治疗von Hippel-Lindau病相关肿瘤

Fallah, Jaleh; Brave, Michael H; Weinstock, Chana; Mehta, Gautam U; Bradford, Diana; Gittleman, Haley; Bloomquist, Erik W; Charlab, Rosane; Hamed, Salaheldin S; Miller, Claudia P; Dorff, Sarah E; Chambers, Wiley A; Mixter, Bronwyn D; Dinin, Jeannette; Pierce, William F; Ricks, Tiffany K; Tang, Shenghui; Donoghue, Martha; Pazdur, Richard; Amiri-Kordestani, Laleh; Ibrahim, Amna; Beaver, Julia A